Argireline, also known as Acetyl Hexapeptide-3 (Ac-EEMQRR-NH₂), is a synthetic peptide sequence structurally derived from the N-terminal domain of SNAP-25, a component of the SNARE protein complex. In laboratory research, Argireline is utilized as a molecular tool to investigate vesicular trafficking, membrane fusion events, and protein–protein interactions involved in regulated exocytosis within in-vitro and preclinical experimental systems.

Peptide Sequence: Ac-Glu-Glu-Met-Gln-Arg-Arg-NH₂ (Ac-EEMQRR-NH₂)
Molecular Formula: C₃₄H₆₀N₁₄O₁₂S
Molecular Weight: 888.99 g/mol

Argireline is a short-chain, acetylated hexapeptide designed to mimic a functional domain of SNAP-25. The peptide’s acetylated N-terminus enhances stability, while its charged residues facilitate competitive binding interactions with SNARE-associated proteins in biochemical assays.

1. SNARE Complex Assembly Studies

Argireline is employed in cell-free and cellular models to examine competitive inhibition of SNAP-25 participation in SNARE complex formation. These studies help elucidate the molecular requirements for vesicle docking and fusion.

2. Neurotransmitter Vesicle Dynamics

In neuronal and neurosecretory cell models, Argireline is used to investigate the modulation of calcium-dependent exocytosis and vesicle release kinetics by altering SNARE protein interactions.

3. Protein–Protein Interaction Assays

Due to its defined binding motif, Argireline serves as a probe for studying SNARE-associated protein interfaces, enabling characterization of binding affinity, conformational changes, and complex stability under controlled experimental conditions.

Mechanistically, Argireline interferes with the SNARE-mediated membrane fusion pathway by competing with endogenous SNAP-25 for binding sites within the SNARE complex. This competitive interaction alters vesicle priming and fusion efficiency, providing researchers with a controllable means of studying exocytotic regulation, synaptic signaling, and intracellular trafficking mechanisms at the molecular level.

Preclinical research involving Argireline includes in-vitro studies using neuronal cell lines, fibroblast cultures, and reconstructed tissue models. These investigations focus on SNARE complex modulation, vesicle trafficking efficiency, and downstream signaling effects. All findings are confined to experimental laboratory systems and are used exclusively to advance understanding of vesicular transport biology.

Argireline is supplied as a purified synthetic peptide suitable for analytical and experimental research workflows. Standard quality control methodologies such as high-performance liquid chromatography (HPLC) and mass spectrometry (MS) are used to confirm peptide identity, molecular weight, and purity prior to release.

1. Blanes-Mira C. et al., “A synthetic hexapeptide (Argireline®) with antiwrinkle activity,” International Journal of Cosmetic Science, 2002; 24(5):303–310.
2. Daines A. M. et al., “SNARE protein inhibition by acetyl hexapeptides: implications for regulated exocytosis,” Peptides, 2010; 31(10):1994–2001.
3. Calvo P. et al., “Biochemical and clinical evaluation of acetyl hexapeptide-3,” Journal of Cosmetic Dermatology, 2015; 14(1):27–35.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.

For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use.